title: Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
abstract: Pyoderma gangrenosum has been described in association with multiple myeloma and usually affects patients with active/untreated disease. This dermatologic condition was shown to resolve after successful anti-myeloma therapy. We report herein occurrence of pyoderma gangrenosum involving bilateral knees in a patient with multiple myeloma responding to lenalidomide therapy. Previous papers claimed usefulness of thalidomide and its newer derivatives for the therapy of this neutrophilic dermatosis. Occurrence of pyoderma gangrenosum in a myeloma patient responding to lenalidomide would argue against its effectiveness in treating this skin condition. Moreover, the clinical setting suggested that lenalidomide either induced or contributed to the occurrence of pyoderma gangrenosum in our patient. If our hypothesis is correct, we expect more reports of pyoderma gangrenosum with the use of this class of pharmaceuticals.
authors.affiliation: Department of Medicine, University of Connecticut, Farmington, CT, USA c_dasanu@yahoo.com.
authors.forename: Constantin A
authors.initials: CA
authors.lastname: Dasanu
authors.affiliation: Department of Medicine, University of Connecticut, Farmington, CT, USA.
authors.forename: Bruno
authors.initials: B
authors.lastname: Bockorny
authors.affiliation: Department of Dermatology, Health Care Partners Medical Group, Mission Hills, CA, USA.
authors.forename: Doru T
authors.initials: DT
authors.lastname: Alexandrescu
mesh_terms: D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D001772:Blood Cell Count; D017809:Fatal Outcome; D006801:Humans; D007717:Knee / Q000473:pathology; D000077269:Lenalidomide; D008297:Male; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy*; D017511:Pyoderma Gangrenosum / Q000139:chemically induced* / Q000473:pathology; D012867:Skin / Q000473:pathology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D000077269:Lenalidomide
keywords: Pyoderma gangrenosum; lenalidomide; multiple myeloma; thalidomide